solange peters
solange peters
Bilinmeyen bağlantı
chuv.ch üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
13482017
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
S Peters, DR Camidge, AT Shaw, S Gadgeel, JS Ahn, DW Kim, SHI Ou, ...
New England Journal of Medicine 377 (9), 829-838, 2017
10902017
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Haanen, F Carbonnel, C Robert, KM Kerr, S Peters, J Larkin, K Jordan
Annals of Oncology 28, iv119-iv142, 2017
9782017
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ...
Annals of Oncology 27, v1-v27, 2016
7102016
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D Planchard, S Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ...
Annals of Oncology 29, iv192-iv237, 2018
693*2018
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Reck, S Popat, N Reinmuth, D De Ruysscher, KM Kerr, S Peters
Annals of oncology 25, iii27-iii39, 2014
6632014
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
PE Postmus, KM Kerr, M Oudkerk, S Senan, DA Waller, J Vansteenkiste, ...
Screening 25, 2, 2017
5532017
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
J Mazieres, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ...
Journal of clinical oncology 31 (16), 1997-2003, 2013
5072013
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
S Peters, AA Adjei, C Gridelli, M Reck, K Kerr, E Felip
Annals of oncology 23, vii56-vii64, 2012
5012012
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J Vansteenkiste, D De Ruysscher, WEE Eberhardt, E Lim, S Senan, ...
Annals of oncology 24, vi89-vi98, 2013
4862013
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Früh, D De Ruysscher, S Popat, L Crinò, S Peters, E Felip
Annals of oncology 24, vi99-vi105, 2013
4332013
Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ...
New England Journal of Medicine 381 (21), 2020-2031, 2019
4302019
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
TA Chan, M Yarchoan, E Jaffee, C Swanton, SA Quezada, A Stenzinger, ...
Annals of Oncology 30 (1), 44-56, 2019
4052019
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ...
The Lancet 395 (10241), 1907-1918, 2020
4022020
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up
J Vansteenkiste, L Crinò, C Dooms, JY Douillard, C Faivre-Finn, E Lim, ...
Annals of Oncology 25 (8), 1462-1474, 2014
3422014
2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer
WEE Eberhardt, D De Ruysscher, W Weder, C Le Péchoux, P De Leyn, ...
Annals of Oncology 26 (8), 1573-1588, 2015
2882015
MET: a promising anticancer therapeutic target
S Peters, AA Adjei
Nature reviews Clinical oncology 9 (6), 314-326, 2012
2732012
Late Ebola virus relapse causing meningoencephalitis: a case report
M Jacobs, A Rodger, DJ Bell, S Bhagani, I Cropley, A Filipe, RJ Gifford, ...
The Lancet 388 (10043), 498-503, 2016
2562016
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
KM Kerr, L Bubendorf, MJ Edelman, A Marchetti, T Mok, S Novello, ...
Annals of Oncology 25 (9), 1681-1690, 2014
2542014
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F Martins, L Sofiya, GP Sykiotis, F Lamine, M Maillard, M Fraga, ...
Nature reviews Clinical oncology 16 (9), 563-580, 2019
2372019
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20